RT Journal
A1 Eberlein TJ, Schoof DD, Michie HR, et al
T1 IBuprofen causes reduced toxic effects of interleukin 2 administration in patients with metastatic cancer
JF Archives of Surgery
JO Archives of Surgery
YR 1989
FD May 1
VO 124
IS 5
SP 542
OP 547
DO 10.1001/archsurg.1989.01410050032005
UL http://dx.doi.org/10.1001/archsurg.1989.01410050032005
AB • Metastatic cancer was treated with interleukin 2 and lymphokine-activated killer cells with the addition of the cyclooxygenase inhibitor ibuprofen in an attempt to reduce side effects in 13 patients (eight male and five female). Twenty-six patients treated with only interleukin 2 and lymphokineactivated killer cells formed the control group. After interleukin 2 administration, a significantly increased number of lymphokine-activated killer cells were transfused in ibuprofentreated patients. Cytotoxic effects were not significantly different in the treated and untreated groups. With regard to cell phenotype, both groups of patients manifested significant activation of the immune system as measured by T10 and OK1a. Symptom scores were dramatically reduced in patients treated with ibuprofen. Temperatures above 37°C were rare. Ibuprofen did not significantly alter rate of response in this immunotherapy trial (38% vs 42%). Ibuprofen is now routinely used in all of our current immunotherapy trials.(Arch Surg. 1989;124:542-547)